keyword
https://read.qxmd.com/read/38629403/skills-training-followed-by-either-emdr-or-narrative-therapy-for-posttraumatic-stress-disorder-in-adult-survivors-of-childhood-abuse-a-randomized-controlled-trial
#41
RANDOMIZED CONTROLLED TRIAL
I Wigard, K Meyerbröker, T Ehring, M Topper, A Arntz, P Emmelkamp
Background: Individuals suffering from PTSD following childhood abuse represent a large subgroup of patients attending mental health services. The aim of phase-based treatment is to tailor treatment to the specific needs to childhood abuse survivors with PTSD with a Skills Training in Affective and Interpersonal Regulation (STAIR) phase, in which emotion dysregulation and interpersonal problems are targeted, and a trauma-focused phase. Objective: The purpose of this study was to compare STAIR + Eye Movement Desensitization and Reprocessing (EMDR) vs...
2024: European Journal of Psychotraumatology
https://read.qxmd.com/read/38629191/safety-tolerability-and-pharmacokinetics-of-anaprazole-a-novel-proton-pump-inhibitor-in-healthy-chinese-subjects
#42
JOURNAL ARTICLE
Fangfang Wang, Xiaoye Niu, Fei Liu, Xifeng Ma, Fang Cheng, Haiyan Xu, Li Wang, Yanjun Xu, Haiyan Li
Anaprazole, a newly developed oral proton pump inhibitor, was evaluated for safety, tolerability, and pharmacokinetics in healthy Chinese subjects. This study involved administering either anaprazole sodium enteric-coated tablet or placebo, followed by monitoring the incidence and severity of any adverse events (AEs). The pharmacokinetic parameters of anaprazole, its isomer, and main metabolisms were determined. The results showed that both single-dose (2.5-120 mg) and multiple-dose (20 mg once daily, 40 mg once daily, or 20 mg twice daily) oral administration of anaprazole sodium enteric-coated tablet were safe and well tolerated...
April 17, 2024: Clinical Pharmacology in Drug Development
https://read.qxmd.com/read/38628803/discovery-of-crn04894-a-novel-potent-selective-mc2r-antagonist
#43
JOURNAL ARTICLE
Sun Hee Kim, Sangdon Han, Jian Zhao, Shimiao Wang, Ana Karin Kusnetzow, Greg Reinhart, Melissa A Fowler, Stacy Markison, Michael Johns, Rosa Luo, R Scott Struthers, Yunfei Zhu, Stephen F Betz
A novel class of nonpeptide melanocortin type 2 receptor (MC2R) antagonists was discovered through modification of known nonpeptide MC4R ligands. Structure-activity relationship (SAR) studies led to the discovery of 17h (CRN04894), a highly potent and subtype-selective first-in-class MC2R antagonist, which demonstrated remarkable efficacy in a rat model of adrenocorticotrophic hormone (ACTH)-stimulated corticosterone secretion. Oral administration of 17h suppressed ACTH-stimulated corticosterone secretion in a dose-dependent manner at doses ≥3 mg/kg...
April 11, 2024: ACS Medicinal Chemistry Letters
https://read.qxmd.com/read/38628695/the-stratified-effects-of-repetitive-transcranial-magnetic-stimulation-in-upper-limb-motor-impairment-recovery-after-stroke-a-meta-analysis
#44
JOURNAL ARTICLE
Ran Li, Sihan Liu, Tianyuan Li, Kun Yang, Xue Wang, Wenjiao Wang
BACKGROUND: The recovery of upper extremity motor impairment after stroke remains a challenging task. The clinical effectiveness of repetitive transcranial magnetic stimulation (rTMS), which is believed to aid in the recovery process, is still uncertain. METHODS: A systematic search was conducted in Medline (Ovid), Cochrane and Embase electronic databases from March 28, 2014, to March 28, 2023. The inclusion criteria consisted of randomized controlled trials that assessed the effects of rTMS on the recovery of upper limb motor impairment among stroke patients...
2024: Frontiers in Neurology
https://read.qxmd.com/read/38628412/teprotumumab-in-thyroid-eye-disease
#45
JOURNAL ARTICLE
Hila Goldberg, Amina I Malik
Thyroid eye disease (TED) is an inflammatory condition involving the periocular and orbital soft tissues, affecting most commonly patients with hyperthyroid disorders. Traditional treatments used for the active phase of the disease range from conservative lubrication for mild symptoms to systemic immunomodulating drugs for moderate-to-severe symptoms. Teprotumumab (Tepezza) is a monoclonal antibody with an inhibitory effect on insulin-like growth factor 1 and is the first Food and Drug Administration (FDA) approved targeted medical therapy for reducing the inflammatory signs and symptoms associated with TED...
2024: Saudi Journal of Ophthalmology: Official Journal of the Saudi Ophthalmological Society
https://read.qxmd.com/read/38627977/contribution-of-tumour-and-immune-cells-to-pd-l1-expression-as-a-predictive-biomarker-in-metastatic-triple-negative-breast-cancer-exploratory-analysis-from-keynote-119
#46
JOURNAL ARTICLE
Javier Cortes, Eric P Winer, Oleg Lipatov, Seock-Ah Im, Anthony Gonçalves, Eva Muñoz-Couselo, Keun Seok Lee, Peter Schmid, Kenji Tamura, Laura Testa, Isabell Witzel, Shoichiro Ohtani, Stephanie Hund, Karina Kulangara, Vassiliki Karantza, Jaime A Mejia, Junshui Ma, Petar Jelinic, Lingkang Huang, Scott K Pruitt, Kenneth Emancipator
The efficacy of pembrolizumab monotherapy versus chemotherapy increased with increasing programmed death ligand 1 (PD-L1) expression, as quantified by combined positive score (CPS; PD-L1 expression on both tumour cells and immune cells) in patients with previously treated metastatic triple-negative breast cancer (mTNBC) in the phase 3 KEYNOTE-119 study. This exploratory analysis was conducted to determine whether the expression of PD-L1 on tumour cells contributes to the predictive value of PD-L1 CPS in mTNBC...
May 2024: Journal of Pathology. Clinical Research
https://read.qxmd.com/read/38627919/evaluating-the-potency-of-zoliflodacin-against-helicobacter-pylori-in%C3%A2-vitro-activity-and-conserved-gyrb-target
#47
JOURNAL ARTICLE
Jing Liu, Jia Jia, Ting Shi, Yuefan Bai, Yanqiang Huang, Liping Zeng, Hongkai Bi
BACKGROUND: The current standard treatment for Helicobacter pylori infection, which involves a combination of two broad-spectrum antibiotics, faces significant challenges due to its detrimental impact on the gut microbiota and the emergence of drug-resistant strains. This underscores the urgent requirement for the development of novel anti-H. pylori drugs. Zoliflodacin, a novel bacterial gyrase inhibitor, is currently undergoing global phase III clinical trials for treating uncomplicated Neisseria gonorrhoeae...
2024: Helicobacter
https://read.qxmd.com/read/38627795/implementation-of-an-antimicrobial-stewardship-program-for-urinary-tract-infections-in-long-term-care-facilities-a-cluster-controlled-intervention-study
#48
JOURNAL ARTICLE
Elisabeth König, Lisa Kriegl, Christian Pux, Michael Uhlmann, Walter Schippinger, Alexander Avian, Robert Krause, Ines Zollner-Schwetz
BACKGROUND: Widespread inappropriate use of antimicrobial substances drives resistance development worldwide. In long-term care facilities (LTCF), antibiotics are among the most frequently prescribed medications. More than one third of antimicrobial agents prescribed in LTCFs are for urinary tract infections (UTI). We aimed to increase the number of appropriate antimicrobial treatments for UTIs in LTCFs using a multi-faceted antimicrobial stewardship intervention. METHODS: We performed a non-randomized cluster-controlled intervention study...
April 16, 2024: Antimicrobial Resistance and Infection Control
https://read.qxmd.com/read/38627638/rimegepant-orally-disintegrating-tablet-75%C3%A2-mg-for-acute-treatment-of-migraine-in-adults-from-china-a-subgroup-analysis-of-a-double-blind-randomized-placebo-controlled-phase-3-clinical-trial
#49
RANDOMIZED CONTROLLED TRIAL
Shengyuan Yu, Aihong Guo, Zhen Wang, Jianguang Liu, Ge Tan, Qian Yang, Mingjie Zhang, Hasiyeti Yibulaiyin, Huisheng Chen, Yongbo Zhang, Robert Croop, Yanhui Sun, Yu Liu, Qian Zhao, Zhihong Lu
BACKGROUND: Rimegepant orally disintegrating tablet (ODT), an oral small-molecule calcitonin gene-related peptide receptor antagonist, is indicated for acute and preventive treatment of migraine in the United States and other countries. Previously, a large clinical trial assessed the efficacy and safety of rimegepant ODT 75 mg for the acute treatment of migraine in adults living in China or South Korea. A post hoc subgroup analysis of this trial was performed to evaluate the efficacy and safety of rimegepant for acute treatment of migraine in adults living in China...
April 16, 2024: Journal of Headache and Pain
https://read.qxmd.com/read/38627266/bright-light-therapy-versus-physical-exercise-to-prevent-co-occurring-depression-in-adolescents-and-young-adults-with-attention-deficit-hyperactivity-disorder-a-multicentre-three-arm-randomised-controlled-pilot-phase-iia-trial
#50
JOURNAL ARTICLE
Jutta S Mayer, Laura Kohlhas, Jacek Stermann, Juliane Medda, Geva A Brandt, Oliver Grimm, Adam D Pawley, Philip Asherson, Judit Palacio Sanchez, Vanesa Richarte, Douwe Bergsma, Elena D Koch, Adrià Muntaner-Mas, Ulrich W Ebner-Priemer, Meinhard Kieser, Wolfgang Retz, Francisco B Ortega, Michael Colla, Jan K Buitelaar, Jonna Kuntsi, Josep A Ramos-Quiroga, Andreas Reif, Christine M Freitag
Depression is common in attention-deficit/hyperactivity disorder (ADHD), but preventive behavioural interventions are lacking. This randomised controlled, pilot phase-IIa trial aimed to study a physical exercise intervention (EI) and bright light therapy (BLT)-both implemented and monitored in an individual, naturalistic setting via a mobile health (m-health) system-for feasibility of trial design and interventions, and to estimate their effects on depressive symptoms in young people with ADHD. Two hundred seven participants aged 14-45 years were randomised to 10-week add-on intervention of either BLT (10,000 lx; daily 30-min sessions) (n = 70), EI (aerobic and muscle-strengthening activities 3 days/ week) (n = 69), or treatment-as-usual (TAU) (n = 68), of whom 165 (80%) were retained (BLT: n = 54; EI: n = 52; TAU: n = 59)...
April 16, 2024: European Archives of Psychiatry and Clinical Neuroscience
https://read.qxmd.com/read/38626769/neoantigen-targeted-dendritic-cell-vaccination-in-lung-cancer-patients-induces-long-lived-t%C3%A2-cells-exhibiting-the-full-differentiation-spectrum
#51
JOURNAL ARTICLE
Joline Ingels, Laurenz De Cock, Dieter Stevens, Rupert L Mayer, Fabien Théry, Guillem Sanchez Sanchez, David Vermijlen, Karin Weening, Saskia De Smet, Nele Lootens, Marieke Brusseel, Tasja Verstraete, Jolien Buyle, Eva Van Houtte, Pam Devreker, Kelly Heyns, Stijn De Munter, Sandra Van Lint, Glenn Goetgeluk, Sarah Bonte, Lore Billiet, Melissa Pille, Hanne Jansen, Eva Pascal, Lucas Deseins, Lies Vantomme, Maarten Verdonckt, Ria Roelandt, Thomas Eekhout, Niels Vandamme, Georges Leclercq, Tom Taghon, Tessa Kerre, Floris Vanommeslaeghe, Annemieke Dhondt, Liesbeth Ferdinande, Jo Van Dorpe, Liesbeth Desender, Frederic De Ryck, Frank Vermassen, Veerle Surmont, Francis Impens, Björn Menten, Karim Vermaelen, Bart Vandekerckhove
Non-small cell lung cancer (NSCLC) is known for high relapse rates despite resection in early stages. Here, we present the results of a phase I clinical trial in which a dendritic cell (DC) vaccine targeting patient-individual neoantigens is evaluated in patients with resected NSCLC. Vaccine manufacturing is feasible in six of 10 enrolled patients. Toxicity is limited to grade 1-2 adverse events. Systemic T cell responses are observed in five out of six vaccinated patients, with T cell responses remaining detectable up to 19 months post vaccination...
April 9, 2024: Cell reports medicine
https://read.qxmd.com/read/38626709/long-term-follow-up-and-exploratory-analysis-of-lenvatinib-in-patients-with-metastatic-or-recurrent-thymic-carcinoma-results-from-the-multicenter-phase-2-remora-trial
#52
JOURNAL ARTICLE
Seiji Niho, Jun Sato, Miyako Satouchi, Shoichi Itoh, Yusuke Okuma, Hidenori Mizugaki, Haruyasu Murakami, Yasuhito Fujisaka, Toshiyuki Kozuki, Kenichi Nakamura, Ryunosuke Machida, Yuichiro Ohe, Toshiyuki Tamai, Hiroki Ikezawa, Noboru Yamamoto
OBJECTIVES: The main objective of this report was to detail the long-term follow-up data from the REMORA study, which investigated the safety and efficacy of lenvatinib in patients with thymic carcinoma. In addition, an exploratory analysis of the association between relative dose intensity (RDI) and the efficacy of lenvatinib is presented. MATERIALS AND METHODS: The single-arm, open-label, phase 2 REMORA study was conducted at eight Japanese institutions. Forty-two patients received oral lenvatinib 24 mg once daily in 4-week cycles until the occurrence of intolerable adverse events or disease progression...
March 30, 2024: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://read.qxmd.com/read/38626649/impact-of-a-diabetes-designed-meal-delivery-service-on-changes-in-hemoglobin-a-1c-and-quality-of-life-in-patients-with-diabetes
#53
JOURNAL ARTICLE
Bryan A Farford, Brian J Eglinger, Lindsey Kane, James N Gilbert, Colleen T Ball
BACKGROUND: Over 34 million Americans have diabetes, and nutrition therapy is essential in self-management. AIMS: The primary aim of the study was to evaluate the impact of meals designed for patients with type 2 diabetes (T2D) through a meal delivery program. The primary outcome was a 3-month change in hemoglobin A1c (HbA1c ). Secondary outcomes included a 3-month change in weight, blood pressure, high-density lipoprotein, low-density lipoprotein, and triglycerides...
April 15, 2024: Diabetes & Metabolic Syndrome
https://read.qxmd.com/read/38626570/postural-control-before-and-after-transitional-locomotor-tasks-in-children-on-the-autism-spectrum-a-case-control-study
#54
JOURNAL ARTICLE
Magdalena Stania, Ewa Emich-Widera, Anna Kamieniarz-Olczak, Beata Kazek, Martyna Swatowska-Wenglarczyk, Grzegorz Juras
BACKGROUND: Instrumented measurements of postural control provide a more accurate insight into the motor development of children with autism. This study aimed to identify postural control deficits in autistic children during quiet standing before and after transient locomotor task. It was hypothesized that the parameters that characterize the trajectory of center of foot pressure (COP) displacement would be higher in autistic children compared to typically developing children. METHODS: Sixteen autistic children aged 6-10 but without a comorbidity diagnosis, were enrolled in the study group...
April 12, 2024: Clinical Biomechanics
https://read.qxmd.com/read/38626437/women-s-representation-as-principal-investigators-among-pediatric-orthopaedic-clinical-trials-an-analysis-of-clinicaltrials-gov
#55
JOURNAL ARTICLE
Amir H Karimi, Robert J Burkhart, Monish Lavu, Aakash K Shah, R Justin Mistovich
INTRODUCTION: Despite recent efforts to increase the participation of women in orthopaedic surgery, there remains a gender gap, particularly when compared with other medical specialties. Acting as a principal investigator (PI) in a clinical trial can give physicians notable exposure and national recognition, which can improve their chances of promotion and tenure. This study aims to assess the proportion of women serving as PIs in pediatric orthopaedic clinical trials, examine associated trial characteristics, and explore geographic distribution...
April 10, 2024: Journal of the American Academy of Orthopaedic Surgeons
https://read.qxmd.com/read/38625698/neoadjuvant-chemo-immunotherapy-for-early-stage-non-small-cell-lung-cancer-a-systematic-review-and-meta-analysis
#56
JOURNAL ARTICLE
Giuseppe Luigi Banna, Mona Ali Hassan, Alessio Signori, Emilio Francesco Giunta, Akash Maniam, Shobana Anpalakhan, Shyamika Acharige, Aruni Ghose, Alfredo Addeo
IMPORTANCE: Randomized clinical trials (RCTs) with neoadjuvant immune checkpoint inhibitors (ICIs) plus chemotherapy (ICI-chemotherapy) for patients with early-stage non-small cell lung cancer (NSCLC) have reported consistent associations with event-free survival (EFS) and pathologic complete response (pCR) pending longer follow-up for overall survival data. OBJECTIVE: To assess the pooled benefit of ICI-chemotherapy in 2-year EFS and pCR among patients with NSCLC and examine the impact of clinical, pathologic, and treatment-related factors...
April 1, 2024: JAMA Network Open
https://read.qxmd.com/read/38625661/ruxolitinib-cream-1-5-a-review-in-non-segmental-vitiligo
#57
REVIEW
Connie Kang
Topical ruxolitinib 1.5% cream (Opzelura® ), a Janus kinase (JAK) inhibitor, is the first treatment to be approved in several countries for use in patients aged ≥ 12 years with non-segmental vitiligo. In the identical phase III TRuE-V1 and TRuE-V2 trials, significantly more ruxolitinib cream recipients were able to achieve statistically significant and clinically meaningful facial and total body repigmentation, as well as reductions in vitiligo noticeability, compared with vehicle recipients...
April 16, 2024: Drugs
https://read.qxmd.com/read/38625495/comparison-of-efficacy-and-safety-of-pd-1-pd-l1-combination-therapy-in-first-line-treatment-of-advanced-nsclc-an-updated-systematic-review-and-network-meta-analysis
#58
JOURNAL ARTICLE
Yanqing Yang, Wei Chen, Lixian Dong, Lian Duan, Pengfei Gao
BACKGROUND: The use of immune checkpoint inhibitors has led to an increase in randomized controlled trials exploring various first-line combination treatment regimens. With the introduction of new PD-1/PD-L1 inhibitors, there are now more clinical options available. For the first time, the AK105 monoclonal antibody Penpulimab, developed in China, was included. The AK105-302 Phase III trial studied the efficacy and safety of Penpulimab combined with chemotherapy in patients with advanced or metastatic squamous NSCLC...
April 16, 2024: Clinical & Translational Oncology
https://read.qxmd.com/read/38623935/effects-of-quinidine-or-rifampin-co-administration-on-the-single-dose-pharmacokinetics-and-safety-of-rilzabrutinib-prn1008-in-healthy-participants
#59
JOURNAL ARTICLE
Christian Rask-Madsen, Suresh Katragadda, Mengyao Li, Sibel Ucpinar, Leslie Chinn, Puneet Arora, Patrick Smith
This open-label, phase 1 study was conducted with healthy adult participants to evaluate the potential drug-drug interaction between rilzabrutinib and quinidine (an inhibitor of P-glycoprotein [P-gp] and CYP2D6) or rifampin (an inducer of CYP3A and P-gp). Plasma concentrations of rilzabrutinib were measured after a single oral dose of rilzabrutinib 400 mg administered on day 1 and again, following a wash-out period, after co-administration of rilzabrutinib and quinidine or rifampin. Specifically, quinidine was given at a dose of 300 mg every 8 hours for 5 days from day 7 to day 11 (N = 16) while rifampin was given as 600 mg once daily for 11 days from day 7 to day 17 (N = 16) with rilzabrutinib given in the morning of day 10 (during quinidine dosing) or day 16 (during rifampin dosing)...
April 16, 2024: Clinical Pharmacology in Drug Development
https://read.qxmd.com/read/38623454/transferring-care-to-enhance-access-to-early-phase-cancer-clinical-trials-protocol-to-evaluate-a-novel-program
#60
JOURNAL ARTICLE
Chika Nwachukwu, Sukh Makhnoon, Marieshia Person, Meera Muthukrishnan, Syed Kazmi, Larry D Anderson, Gurbakhash Kaur, Kandice A Kapinos, Erin L Williams, Oluwatomilade Fatunde, Navid Sadeghi, Fabian Robles, Alice Basey, Thomas Hulsey, Sandi L Pruitt, David E Gerber
Involving diverse populations in early-phase (phase I and II) cancer clinical trials is critical to informed therapeutic development. However, given the growing costs and complexities of early-phase trials, trial activation and enrollment barriers may be greatest for these studies at healthcare facilities that provide care to the most diverse patient groups, including those in historically underserved communities (e.g., safety-net healthcare systems). To promote diverse and equitable access to early-phase cancer clinical trials, we are implementing a novel program for the transfer of care to enhance access to early-phase cancer clinical trials...
June 2024: Contemporary Clinical Trials Communications
keyword
keyword
48709
3
4
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.